Journals / Medicine Science / 2020 / Cilt: 9 - Sayı: 3

Comparison of biochemical parameters of prevalent hemoglobinopathies with healthy individuals

Pages
708–713
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Thus, a broader, comprehensive national screening program is needed.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Thalassemia is the most frequently seen monogenetic disorders around the world that is inherited as a recessive single-gene disease, resulting from mutations in α-or β-globin gene clusters.
📊
Key Findings & Data:In this study Beta Thalassemia Intermedia, Beta Thalassemia Minor, Sickle Cell Disease patients and the healthy control individuals both incidence and serum parameters were examined and analyzed retrospectively between 2015-2017 from Public Health information system.
💡
Conclusion & Impact:Thus, a broader, comprehensive national screening program is needed.
🔬Design:Research Article
📍Scope:2015-2017 Verileri
⚙️Variables:Domain Parameters

Özet

Thalassemia is the most frequently seen monogenetic disorders around the world that is inherited as a recessive single-gene disease, resulting from mutations in α-or β-globin gene clusters. In this study Beta Thalassemia Intermedia, Beta Thalassemia Minor, Sickle Cell Disease patients and the healthy control individuals both incidence and serum parameters were examined and analyzed retrospectively between 2015-2017 from Public Health information system. Beta Thalassemia Intermedia, Beta Thalassemia Major, Beta Thalassemia Minor and Sickle Cell Disease patient groups incidences were evaluated on the basis of their HPLC analysis. Patients and control groups serum parameters levels were analyzed from their autoanalyzer results. These serum biochemical tests datas were controlled and taken from Siirt Public Health Centre information system. In each year, there were recorded approximately 12 Beta Talassemia patients, 2 Beta Thallassemia Major patients, 340 Beta Thalassemia Minor patients and 33 Sickle Cell Disease patients.Beta Thalassemia Intermedia patients serum parameters levels were compared with Beta Thalassemia Minor Patients serum parameters and control group serum levels. There were seen statisticaly significant difference between Beta Thalassemia Intermedia patient’s serum ast, albumin, creatine, amylase, phosphor, iron, iron binding capacity, total protein, sodium, bilirubin direct, bilirubin total, LDH level and control serum parameters levels, p<0.05. But there were not seen statistically significant differences between Beta Thalassemia Minor patients serum levels and control serum levels. Studies like this should be done nationwide, in each city to determine the current state of abnormal hemoglobinopathies in Turkey. Thus, a broader, comprehensive national screening program is needed.

🔖

Cite This Article

YERLİKAYA, E., KARAGEÇİLİ, H., KAYA, M. O. (2020). Comparison of biochemical parameters of prevalent hemoglobinopathies with healthy individuals. Medicine Science, Cilt: 9 - Sayı: 3, 708–713. https://ajindex.com/articles/276827

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (13)

  1. Ayyıldız H, Arslan TS. Determination of the effect of red blood cell parameters in thediscrimination of iron deficiency anemia and beta BT via Neighborhood Component Analysis Feature Selection-Basedmachine learning. Chemom Intell Lab Syst. 2020;196:103886
  2. Larissia K, Politouc M, Margeli A, et al. The Growth Differentiation Factor-15 (GDF-15) levels are increased in patients with compound heterozygous sickle cell and beta-BT (HbS/βthal), correlate with markers of hemolysis, iron burden, coagulation, endothelial dysfunction and pulmonary hy. Blood Cells Molecul Diseas. 2019;77:137–41
  3. Tang WJ, Zhang CL, Lu FF, et al. Spectrum of α-BT and β-BT mutations in the guilin region of southern china. Clin Biochemist. 2015;48:1068–72
  4. Risoluti R, Materazzi S, Sorrentino F, et al. Thermogravimetric analysis coupled with chemometrics as a powerful predictive tool for beta-BT screening. Talanta. 2016;159:425-32
  5. El Sayed SM, Abou-Taleb A, Mahmoud HS, et al. Percutaneous excretion of iron and ferritin (through Al-hijamah) as a novel treatment for iron overload in beta-BT major, hemochromatosis and sideroblastic anemia. Med Hypotheses. 2014;83:238-46
  6. Shaha F, Sayani F, Trompeter S, et al. Challenges of blood transfusions in β-BT. Blood Reviews. 2019;37:100588
  7. Correia GJ, Moreira N, Eduardo CAC, et al. Partial Splenectomy in the treatment of an adult with BTintermedia: A case report. Int J Surg Case Reports. 2017;41:446–9
  8. Pazgal I, Inbar E, Cohen M, et al. High incidence of silent cerebral infarcts in adult patients with beta BT major. Thrombos Resh. 2016;119–22
  9. Han WP, Huang L, Li YY, et al. Reference intervals for HbA2 and HbF and cut-off value of HbA2 for β-BT carrier screening in a Guizhou population of reproductive age. Clin Biochemist. 2019;65:24–8
  10. Tsilingiris D, Makrilakis K, Voskaridou E, et al. Effect of heterozygous beta BT on HbA1c levels in individuals without diabetes mellitus: A cross sectional study. Clinica Chimica Acta. 2019;494:132–7
  11. AlAgha AS, Faris H, Hammo BH, et al. Identifying β-BT carriers using a data mining approach: The case of the Gaza Strip, Palestine. Artificial Intelligence In Medicine. 2018;88:70–83
  12. Ulusoy MO, Turk H, Kıvanc SA. Spectral domain optical coherence tomography findings in Turkish sickle-cell disease and beta BT major patients. J Current Ophthalmol. 2019;31:275-80
  13. Sirirat K, Sriwantana T, Kaewchuchuen J, et al. Pharmacokinetics and pharmacodynamics of single dose of inhaled nebul